We are live on
!
Find out more
PBM
Propel Bio Management Portfolio holdings
AUM
$191M
Turnover
36.59%
1-Year Est. Return
102.42%
This Fund
S&P 500
This Quarter
Est. Return
+17.45%
1 Year Est. Return
+102.42%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$99.9M
AUM Growth
+$17.5M
(+21%)
Cap. Flow
+$8.31M
Cap. Flow
% of AUM
8.32%
Top 10 Holdings %
Top 10 Hldgs %
87.06%
Holding
21
New
5
Increased
2
Reduced
3
Closed
5
Avg Time Held
0.9
years
Top 10 Avg Time Held
1.1
years
Top 20 Avg Time Held
0.9
years
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Milestone Pharmaceuticals
MIST
|
+$5.86M |
| 2 |
Celldex Therapeutics
CLDX
|
+$3.59M |
| 3 |
Jasper Therapeutics
JSPR
|
+$3.12M |
| 4 |
Delcath Systems
DCTH
|
+$2.37M |
| 5 |
Compass Pathways
CMPS
|
+$2.29M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Achieve Life Sciences
ACHV
|
+$6.5M |
| 2 |
Phathom Pharmaceuticals
PHAT
|
+$3.82M |
| 3 |
Capricor Therapeutics
CAPR
|
+$695K |
| 4 |
EIGR
Eiger BioPharmaceuticals, Inc.
EIGR
|
+$423K |
| 5 |
TScan Therapeutics
TCRX
|
+$274K |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 76.77% |
| 2 | Energy | 23.23% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
1
Plains GP Holdings
PAGP
$5.37B
| $23.2M | 23.23% |
1,272,360
| – | – |
2024 Q2
5 quarters
|
|
|
2
Achieve Life Sciences
ACHV
$722M
| $11.9M | 11.94% |
3,786,425
-2,366,666
| -38% | -$6.5M |
2024 Q1
6 quarters
|
|
3
DELISTED
Akero Therapeutics
AKRO
| $10.9M | 10.88% |
228,884
| – | – |
2023 Q4
7 quarters
|
|
|
4
Milestone Pharmaceuticals
MIST
$98.1M
| $10.2M | 10.26% |
5,124,890
+3,333,333
| +186% | +$5.86M |
2025 Q1
2 quarters
|
|
5
DELISTED
Applied Therapeutics
APLT
| $6.83M | 6.83% |
11,285,420
| – | – |
2023 Q4
7 quarters
|
|
|
6
Phathom Pharmaceuticals
PHAT
$599M
| $6.51M | 6.51% |
552,927
-370,000
| -40% | -$3.82M |
2023 Q4
7 quarters
|
|
7
Abeona Therapeutics
ABEO
$249M
| $5.14M | 5.15% |
974,022
| – | – |
2024 Q2
5 quarters
|
|
|
8
Delcath Systems
DCTH
$511M
| $4.71M | 4.72% |
438,509
+212,457
| +94% | +$2.37M |
2024 Q4
3 quarters
|
|
|
9
Celldex Therapeutics
CLDX
$2.19B
| $4.01M | 4.01% |
+155,000
| New | +$3.59M |
2025 Q3
0 quarters
|
|
|
10
TScan Therapeutics
TCRX
$14.3M
| $3.52M | 3.52% |
1,932,304
-154,835
| -7% | -$274K |
2023 Q4
7 quarters
|
|
|
11
Compass Pathways
CMPS
$1.56B
| $2.92M | 2.93% |
+510,000
| New | +$2.29M |
2025 Q3
0 quarters
|
|
12
Nektar Therapeutics
NKTR
$1.26B
| $2.79M | 2.79% |
+49,000
| New | +$1.62M |
2025 Q3
0 quarters
|
|
|
13
Jasper Therapeutics
JSPR
$16.7M
| $2.45M | 2.45% |
+1,028,806
| New | +$3.12M |
2025 Q3
0 quarters
|
|
14
Zevra Therapeutics
ZVRA
$607M
| $2.21M | 2.21% |
231,874
| – | – |
2024 Q3
4 quarters
|
|
15
Viridian Therapeutics
VRDN
$2.08B
| $1.94M | 1.94% |
+90,000
| New | +$1.62M |
2025 Q3
0 quarters
|
|
16
LeonaBio Inc
LONA
$50.8M
| $618K | 0.62% |
149,279
| – | – |
2023 Q4
7 quarters
|
|
|
17
Capricor Therapeutics
CAPR
$383M
| – | – |
-70,000
| Closed | -$695K | – |
|
|
EIGR
18
DELISTED
Eiger BioPharmaceuticals, Inc.
EIGR
| – | – |
-146,381
| Closed | -$423K | – |
|
Similar funds
CFG
MWM
ALWM
PFA
NWM
MCA
EMCIP
HPM
Propel Bio Management's Q3 2025 Portfolio in Review
As of Q3 2025, Propel Bio Management held 21 positions worth $99.9M, up 21% from $82.4M the previous quarter. Its ten largest holdings account for 87% of the portfolio.
Propel Bio Management deployed $8.31M of net new capital in Q3 2025, opening 5 new positions and adding to 2 existing holdings. Its largest new stake was Celldex Therapeutics: 155,000 shares worth $4.01M.
By sector, the portfolio is most concentrated in Healthcare at 77% of assets, up from 69% a quarter earlier, followed by Energy.
On the sell side, the largest reduction was Achieve Life Sciences, an estimated $6.5M trimmed.
- Propel Bio Management's largest Q3 2025 buy was Celldex Therapeutics: 155,000 shares worth $4.01M.
- Propel Bio Management added most to Milestone Pharmaceuticals in Q3 2025, an estimated $5.86M increase.
- Propel Bio Management's biggest Q3 2025 reduction was Achieve Life Sciences, cutting an estimated $6.5M.
- Propel Bio Management fully exited Capricor Therapeutics in Q3 2025, selling an estimated $695K.
- Propel Bio Management's ten largest holdings make up 87% of its $99.9M portfolio in Q3 2025.
- Propel Bio Management opened 5 new positions and closed 5 in Q3 2025.
- Propel Bio Management's portfolio value rose 21% quarter-over-quarter to $99.9M.
Based on Propel Bio Management's 13F filing for Q3 2025, filed 12 Nov 2025.